Kevin P Weinfurt1,2, Li Lin1, Deborah Watkins Bruner3, Jill M Cyranowski4, Carrie B Dombeck1, Elizabeth A Hahn5,6, Diana D Jeffery7, Richard M Luecht8, Susan Magasi9, Laura S Porter2, Jennifer Barsky Reese10, Bryce B Reeve11, Rebecca A Shelby2, Ashley Wilder Smith12, John T Willse8, Kathryn E Flynn13. 1. Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA. 2. Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, USA. 3. Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, GA, USA. 4. Departments of Psychiatry and Psychology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. 5. Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 6. Center for Patient-Centered Outcomes, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 7. Department of Defense-Health Affairs, TRICARE Management Activity, Falls Church, VA, USA. 8. Department of Educational Research Methodology, School of Education, University of North Carolina at Greensboro, Chicago, IL, USA. 9. Department of Occupational Therapy, University of Illinois at Chicago, Chicago, IL, USA. 10. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, USA. 11. Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 12. Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA. 13. Center for Patient Care and Outcomes Research, Medical College of Wisconsin, Milwaukee, WI, USA.
Abstract
INTRODUCTION: The Patient-Reported Outcomes Measurement Information System (PROMIS)(®) Sexual Function and Satisfaction measure (SexFS) version 1.0 was developed with cancer populations. There is a need to expand the SexFS and provide evidence of its validity in diverse populations. AIM: The aim of this study was to describe the development of the SexFS v2.0 and present preliminary evidence for its validity. METHODS: Development built on version 1.0, plus additional review of extant items, discussions with 15 clinical experts, 11 patient focus groups (including individuals with diabetes, heart disease, anxiety, depression, and/or are lesbian, gay, bisexual, or aged 65 or older), 48 cognitive interviews, and psychometric evaluation in a random sample of U.S. adults plus an oversample for specific sexual problems (2281 men, 1686 women). We examined differential item functioning (DIF) by gender and sexual activity. We examined convergent and known-groups validity. RESULTS: The final set of domains includes 11 scored scales (interest in sexual activity, lubrication, vaginal discomfort, clitoral discomfort, labial discomfort, erectile function, orgasm ability, orgasm pleasure, oral dryness, oral discomfort, satisfaction), and six nonscored item pools (screeners, sexual activities, anal discomfort, therapeutic aids, factors interfering with sexual satisfaction, bother). Domains from version 1.0 were reevaluated and improved. Domains considered applicable across gender and sexual activity status, namely interest, orgasm, and satisfaction, were found to have significant DIF. We identified subsets of items in each domain that provided consistent measurement across these important respondent groups. Convergent and known-groups validity was supported. CONCLUSIONS: The SexFS version 2.0 has several improvements and enhancements over version 1.0 and other extant measures, including expanded evidence for validity, scores centered around norms for sexually active U.S. adults, new domains, and a final set of items applicable for both men and women and those sexually active with a partner and without. The SexFS is customizable, allowing users to select relevant domains and items for their study.
INTRODUCTION: The Patient-Reported Outcomes Measurement Information System (PROMIS)(®) Sexual Function and Satisfaction measure (SexFS) version 1.0 was developed with cancer populations. There is a need to expand the SexFS and provide evidence of its validity in diverse populations. AIM: The aim of this study was to describe the development of the SexFS v2.0 and present preliminary evidence for its validity. METHODS: Development built on version 1.0, plus additional review of extant items, discussions with 15 clinical experts, 11 patient focus groups (including individuals with diabetes, heart disease, anxiety, depression, and/or are lesbian, gay, bisexual, or aged 65 or older), 48 cognitive interviews, and psychometric evaluation in a random sample of U.S. adults plus an oversample for specific sexual problems (2281 men, 1686 women). We examined differential item functioning (DIF) by gender and sexual activity. We examined convergent and known-groups validity. RESULTS: The final set of domains includes 11 scored scales (interest in sexual activity, lubrication, vaginal discomfort, clitoral discomfort, labial discomfort, erectile function, orgasm ability, orgasm pleasure, oral dryness, oral discomfort, satisfaction), and six nonscored item pools (screeners, sexual activities, anal discomfort, therapeutic aids, factors interfering with sexual satisfaction, bother). Domains from version 1.0 were reevaluated and improved. Domains considered applicable across gender and sexual activity status, namely interest, orgasm, and satisfaction, were found to have significant DIF. We identified subsets of items in each domain that provided consistent measurement across these important respondent groups. Convergent and known-groups validity was supported. CONCLUSIONS: The SexFS version 2.0 has several improvements and enhancements over version 1.0 and other extant measures, including expanded evidence for validity, scores centered around norms for sexually active U.S. adults, new domains, and a final set of items applicable for both men and women and those sexually active with a partner and without. The SexFS is customizable, allowing users to select relevant domains and items for their study.
Authors: Bryce B Reeve; Mian Wang; Kevin Weinfurt; Kathryn E Flynn; Deborah S Usinger; Ronald C Chen Journal: J Sex Med Date: 2018-10-24 Impact factor: 3.802
Authors: Diana D Jeffery; Lisa Barbera; Barbara L Andersen; Amy K Siston; Anuja Jhingran; Shirley R Baron; Jennifer Barsky Reese; Deborah J Coady; Jeanne Carter; Kathryn E Flynn Journal: J Psychosoc Oncol Date: 2015
Authors: Kathryn E Flynn; Jeanne Carter; Li Lin; Stacy T Lindau; Diana D Jeffery; Jennifer Barsky Reese; Bethanee J Schlosser; Kevin P Weinfurt Journal: Am J Obstet Gynecol Date: 2016-12-14 Impact factor: 8.661
Authors: John M Salsman; Suzanne C Danhauer; Justin B Moore; Mollie R Canzona; David E Victorson; Bradley J Zebrack; Bryce B Reeve Journal: Cancer Date: 2020-09-10 Impact factor: 6.860
Authors: Jennifer Barsky Reese; Kristen Sorice; Stephen J Lepore; Mary B Daly; James A Tulsky; Mary Catherine Beach Journal: Patient Educ Couns Date: 2018-10-04
Authors: Maisa I Abdalla; Robert S Sandler; Michael D Kappelman; Christopher F Martin; Wenli Chen; Kristen Anton; Millie D Long Journal: Inflamm Bowel Dis Date: 2016-11 Impact factor: 5.325
Authors: Kathryn E Flynn; Li Lin; Deborah Watkins Bruner; Jill M Cyranowski; Elizabeth A Hahn; Diana D Jeffery; Jennifer Barsky Reese; Bryce B Reeve; Rebecca A Shelby; Kevin P Weinfurt Journal: J Sex Med Date: 2016-09-23 Impact factor: 3.802